Article Text
PDF
Statistics from Altmetric.com
Q In postmenopausal women with osteoporosis, does a once yearly intravenous infusion of zoledronic acid reduce the incidence of fractures?
Clinical impact ratings GP/FP/Primary care ★★★★★★☆ IM/Ambulatory care ★★★★★★★ Rheumatology ★★★★★★★ Endocrine ★★★★★★☆ Geriatrics ★★★★★★☆
METHODS
Design:
randomised placebo controlled trial (Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly [HORIZON]).
Allocation:
not concealed.*
Blinding:
blinded (outcome assessors).*
Follow-up period:
36 months.
Setting:
clinics in 25 countries in Europe, North and Latin America, Australia, and Asia.
Patients:
7765 postmenopausal women (mean age 73 y) with a bone mineral density T score ⩽2.5 at the femoral neck, with or without vertebral fractures, or with a T score ⩽1.5 and ⩾2 mild or 1 moderate vertebral fractures. Women were grouped as stratum 1 (n = 6113) if they were not taking …
Linked Articles
- Glossary